

CURRICULUM VITAE

ALEXANDER BYSTRITSKY, M.D., Ph.D.

PERSONAL INFORMATION

Brainsonix Corp./CalNeuro/WSNT/ ABCanxiety
10780 Santa Monica Blvd, Suite 470
Los Angeles, CA 90025
Tel/Fax 310-943-6983

UCLA Neuropsychiatric Institute and Hospital
300 UCLA Medical Plaza, Suite 2340, Los Angeles, CA 90024
Business Tel.: (310) 206-5177

Born: January 18, 1954; Leningrad, U.S.S.R.
Citizen of U.S.A.

EDUCATION

1971-1977

Pavlov Medical University, St. Petersburg, Russia
M.D.

1977-1979

Pavlov Medical University, St. Petersburg, Russia
Ph.D. (equivalent) – Psychopharmacology

1981-1985

New York University-Bellevue Medical Center, New York, NY
Resident in Psychiatry (Chief Resident of Anxiety Disorders
Program as PGY-4)

1985-1987

University of California, Los Angeles, Los Angeles, CA
Robert Wood Johnson Clinical Scholar

2003-2006

Ph.D. degree in Clinical Psychiatry and Neuropharmacology,
St. Petersburg Medical University,

LICENSURE

State of California # A04132
State of New York # 159550
(inactive)

BOARD CERTIFICATION

American Board of Psychiatry and Neurology # 30209

PROFESSIONAL EXPERIENCE

Present positions:

CEO, Brainsonix Corporation, Los Angeles, California
Co-Founder/Executive Director Emeritus and Advisory Board Member,
Tiny Blue Dot Foundation, Santa Monica, California
Co-Founder and President, Institute for Advanced Consciousness Studies,
Santa Monica, California
Founder and President, ABCanxiety. Inc, Los Angeles, California
President, Pacific Institute of Medical Research, Los Angeles, CA
Co-Founder and Principal Investigator, CalNeuro, Inc., Los Angeles, CA
Co-Founder and Principal Physician, WestSide NeuroTherapeutics
Co-Founder Synaptic Research, Los Angeles, California
Professor Emeritus of Psychiatry and Biobehavioral Sciences,
UCLA, David Geffen School of Medicine
Director Emeritus and Supervising Faculty, Anxiety Disorder
Program and Targeted Brain Stimulation Program,
At Semel Institute of Neuroscience and Human Behavior, UCLA,
David Geffen School of Medicine, Los Angeles, CA
Training Director in Interventional Psychiatry, Mission Community
Medical Center, Los Angeles California

1977-1979	Ph.D. Candidate Pavlov Medical University, St. Petersburg, Russia Institute of Experimental Medicine
1980-1981	Assistant Research Scientist New York University Medical Center
1981-1985	Resident in Psychiatry (Chief Resident of Anxiety Disorders Program as PGY-4) New York University-Bellevue Medical Center, New York, NY
1985-1987	Robert Wood Johnson Clinical Scholar University of California, Los Angeles, Los Angeles, CA
1987-2020	Director of Anxiety Disorders Program (Founder) Neuropsychiatric Institute and Hospital University of California, Los Angeles, Los Angeles, CA
1987-2009	Director of Outpatient Psychopharmacology Neuropsychiatric Institute and Hospital University of California, Los Angeles, Los Angeles, CA
1990-	Attending Physician, Neuropsychiatric Hospital University of California, Los Angeles, Los Angeles, CA
1991-2009	Director, Partial Hospitalization Program for Treatment Resistant Anxiety Disorder, Neuropsychiatric Hospital (Co-Founder) University of California, Los Angeles, Los Angeles, CA
1997 - 2000	Associate Director, Clinical Psychopharmacology Research Center Neuropsychiatric Institute and Hospital University of California, Los Angeles, Los Angeles, CA
2007 - 2011	Visiting Professor at Full Professor Level, Neuroscience and Radiology, Brigham and Women's Hospital, Harvard School of Medicine, Boston, Massachusetts
2003-	President and CEO, Brainsonix Corporation, Sherman Oaks, CA (Founder)
2004-2018	Director, Targeted Brain Stimulation, UCLA, Semel Institute Neuroscience and Human Behavior, Los Angeles, CA

Curriculum Vitae**Alexander Bystritsky, M.D., Ph.D.**

2015-2020	Executive Director, Tiny Blue Dot Foundation, Santa Monica, CA (Co-Founder)
2018-	President, ABCanxiety, Inc, a Specialized Clinical Practice Los Angeles, CA (Founder)
2018-	Principal Investigator, CalNeuro, Inc, a Clinical Trial Site Los Angeles, CA (Co-Founder)
2018-	Chief Medical Officer, West Side Neurotherapeutics, Inc, Los Angeles CA (Co-Founder)
2019 -	President, Institute for Advanced Consciousness Studies Santa Monica, CA (Co-Founder)
2019 -	Chief Scientific Officer of Synaptic Research (Co-Founder)

PROFESSIONAL ACTIVITIES**Memberships**

American Psychiatric Association (DLF)
 Southern California Psychiatric Society
 Anxiety Disorders Association of America
 Western Coast College of Biological Psychiatry
 OCD Foundation
 College Internationale Neuro Psychopharmacology
 American Society of Clinical Psychopharmacology (LF)

Committee/Community/Teaching Service

1986-2007 Volunteer Psychiatric Consultant for The Russian-American Society and Jewish Community Services of Los Angeles
 1987-2018 Member, UCLA Pharmacy and Therapeutics Committee
 1987- PGY 2-4 Residents' Supervisor
 1987- Lecturer for UCLA Clinical Pharmacology Course
 1994- Expert Treatment Panel of Anxiety Disorders Association of America
 1995-2011 Chair, Committee on Clinical Trials, American Society for Clinical Psychopharmacology
 1995-1998 Chair, Committee on International Affairs, Southern California Psychiatric Society
 1997-2007 Member, Scientific Advisory Board, OCD Foundation, Western Region
 1997-2011 Treatment and Assessment Consultant for Anxiety Disorders Rand Corporation, Santa Monica

Editorial Service

1987- Reviewer for Archives of General Psychiatry
 1989- Reviewer for Journal of Anxiety Disorders
 1990- Reviewer for American Journal of Psychiatry
 1993- Reviewer for Journal of Nervous Mental Disorder
 1993- Reviewer for Depression and Anxiety
 1994- Reviewer for Journal of Geriatric Psychiatry
 2003- Invited Guest Editor for Focus Publications
 2011-2016 Associate Editor, Brain and Behavior
 2014-2022 Editor, American Society Clinical Psychopharmacology Website
 2014- 2023 Chief Editor, Anxiety.org

HONORS AND SPECIAL AWARDS

1975	Best Student Research Paper Leningrad.
1976	Gold Medal for Best Student Research Paper in U.S.S.R. among Medical, Physical and Mathematical Sciences
1977	Maria Petrova Award - The Most Outstanding Young Scientist Paper in the fields of Psychiatry and Neurology in the U.S.S.R.
1985	Robert Wood Johnson Clinical Scholar
1994	Bristol Myers Distinguished Faculty
1994	Janssen Clinical Scholar
1994	Special Recognition Service Award, SCPA
1995-	Who's Who in the United States, #16531
1996	Physician Recognition Award, California Medical Association
1996	Best Doctors in Los Angeles, LA Magazine Listing
1998-	Best Doctors in America
1999-	Who is Who in the World
2000-	America's Top Doctors
2001-	Distinguished Life Fellow of American Psychiatric Association
2005-	Man of the Year Listings
2005	OC Foundation Research Award
2009	NARSAD Distinguished Investigator Award
2013	Catholic University of Incheon, South Korea Research Award
2016	Life Fellow American Society of Clinical Psychopharmacology
2016	Wired Magazine, Best Things in The World, 2016
2018	Professor Emeritus, UCLA
2024	Sigma X Honorary Research Society

PUBLICATION/BILIOGRAPHY**RESEARCH PAPERS (peer reviewed)**

1. Rabey JM, Passeltiner P, **Bystritsky A**, Engel J, Goldstein M. The regulation of striatal dopa synthesis by alpha-2 adrenoreceptors, Brain Res, 230:422-426, 1981.
2. Goldstein M, Engel J, **Bystritsky A**, Mino S. Therapeutic potentials of centrally acting dopamine and alpha-2 receptor agonists, J Neural Transm, 18:257-265, 1983.
3. Fogelson DL, **Bystritsky A**, Sussman N. Interrelationships between major depression and the anxiety disorders: Clinical relevance, Psychiatric Annals, 18:31 158-167, 1988.
4. Fogelson D, **Bystritsky A**, Katz R, DeVeaugh-Geiss J, Landau P. Obsessive-compulsive disorder treatment response to clomipramine hydrochloride and influence of affective disturbance, Biol Psychiatry, (Supplement) 25:184a-193a, 1989.
5. Pasnau RO, **Bystritsky A**. Overview of anxiety disorders. Bull Menninger Clin, 54(2):157-169, 1990.
6. Pasnau RO, **Bystritsky A**. The importance of treating anxiety in elderly ill patients, Psychiatric Medicine, 8(3):163-173, 1990.
7. **Bystritsky A**, Ware JE, Linn LS. Development of a multidimensional scale of anxiety, Journal of Anxiety Disorders, 4:99-115, 1990.
8. Levine S, Anderson D, **Bystritsky A**, Baron D. A report of eight HIV-seropositive patients with major depression responding to fluoxetine, J Acquir Immune Defic Syndr, 3:1074-1077, 1990.
9. **Bystritsky A**, Pasnau RO. Initial reaction and response to antidepressants, Am J Psychiatry, 147:11:1575, 1990.
10. **Bystritsky A**, Ackerman DL, Pasnau RO. Low dose desipramine treatment of cocaine related panic attacks, J Nerv Ment Dis, 179:755-758, 1991.
11. **Bystritsky A**, Pasnau RO. Switching from alprazolam to buspirone, J Clin Psychopharmacol, 11:3:219-220, 1991.
12. Fogelson DL, **Bystritsky A**. Imipramine in the treatment of obsessive compulsive disorder with and without depression, Ann Clin Psychiatry, 3:3:1230-1237, 1991.
13. Levine S, **Bystritsky A**, Barron D, Jones L. Group psychotherapy for HIV-seropositive patients with major depression, Am J Psychother, XLV:2:112-116, 1991.

14. Fogelson DL, **Bystritsky A**, Pasnau RO. Bupropion in the treatment of bipolar disorders: The same old story, J Clin Psychiatry, 53:443-446, 1992.
15. Davis KL and the Tacrine Collaborative Study Group (**Bystritsky** named as member). A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease, N Engl J Med, 327(18):1253-1259, 1992.
16. **Bystritsky A**, Shapiro D. Continuous physiological and subjective reports in panic patients: A preliminary methodological report, Biol Psychiatry, 32:766-777, 1992.
17. **Bystritsky A**, Fogelson DL, Doctor R, Yager J. Symptom differences among patients in clinics with differing treatment orientations, Am J Psychother, 2:2:164-170, 1993.
18. **Bystritsky A**, Stoessel P, Yager J. Psychometric discrimination between anxiety and depression, J Nerv Ment Dis, 181:4:265-267, 1993.
19. Katz RJ, Landau PS, Lott M, **Bystritsky A**, Diamond B, Hoehn-Saric R, Rosenthal M, Schweizer E, Weise C. Serotonergic (5-HT₂) mediation of anxiety-therapeutic effects of serazepine in generalized anxiety disorders: 5-HT₂, Biol Psychiatry, 34:41-44, 1993.
20. Mendels J, Johnston R, Mattes J, Riesenbergr R (An Expert's Group, **Bystritsky** named as member). Efficacy and safety of b.i.d. doses of venlafaxine in a dose- response study, Psychopharmacol Bull, 29:169-174, 1993.
21. Sherbourne CD, Wells KB, Judd LL, with Panic Disorder Outcome Study Team, (An Expert's Group, **Bystritsky** named as member). Rand Publication, 1994.
22. Shear MK, Maser J, (An Expert's Group, **Bystritsky** named as member). Standardized assessment for panic disorder research, Arch Gen Psychiatry, 51:346-364, 1994.
23. Ackerman DL, Greenland S, **Bystritsky A**, Morgenstern H, Katz RJ. Predicators of treatment response in obsessive compulsive disorder: Multivariate analyses from a multicenter trial of clomipramine, J Clin Psychopharmacol, 14:4:247-254, 1994.
24. **Bystritsky A**, Waikar SV. Inert placebo versus active medication: Patient blindability in clinical pharmacological trials, J Nerv Mental Dis, 182:9:485-487, 1994.
25. Targ EF, Karasic DH, Diefenbach PN, Anderson DA, **Bystritsky A**, Fawzy FI. Structured group therapy and fluoxetine to treat depression in HIV-positive persons, Psychosomatics, 35:(2):132-137, 1994.
26. Waikar SV, **Bystritsky A**, Craske MG, Murphy KJ. Etiological beliefs and treatment seeking behavior in anxiety-disordered patients, Anxiety, 1:134-137, 1995.

27. **Bystritsky A**, Rosen RM, Murphy KJ, Bohn P, Keys SA, Vapnik T. Double-blind pilot trial of desipramine vs. fluoxetine in panic patients, J of Anxiety Disorders, 1:287-290, 1995.
28. Stoessel PW, **Bystritsky A**, Pasnau RO. Distinguishing anxiety disorders patients from medical patients in the outpatient medical setting, Family Practice, 12:448-451, 1995.
29. **Bystritsky A**, Craske M, Maidenberg E, Vapnik T, Shapiro D. Ambulatory monitoring of panic patients during regular activity: A preliminary report. Biol Psychiatry, 38:10:684-689, 1995.
30. Craske MG, Maidenberg E, **Bystritsky A**. Brief cognitive-behavioral versus nondirective therapy for panic disorder, J Behav Ther Exp Psychiatry, 26:113-120, 1995.
31. **Bystritsky A**, Waikar S, Vapnik T. The four-dimensional anxiety and depression scale, Anxiety, 2:47-50, 1995.
32. Small GW, Hamilton SH, **Bystritsky A**, Meyers BS, Nemeroff CB. Clinical response predictors in a double-blind, placebo-controlled trial of fluoxetine for geriatric major depression, Int Psychogeriatr, 7:41-53, 1995.
33. **Bystritsky A**, Munford PR, Rosen RM, Martin KM, Vapnik T, Gorbis EE, Wolson RC. A preliminary study of partial hospital management of severe obsessive-compulsive disorder, Psychiatr Serv, 47:170-174, 1996.
34. Ackerman DL, Greenland S, **Bystritsky A**. Use of receiver-operator characteristic (ROC) curve analysis to evaluate predictors of response to clomipramine therapy, Psychopharmacol Bull, 32:157-165, 1996.
35. Small GW, Schneider LS, Holman SL, **Bystritsky A**. Site variability in multicenter geriatric desipramine trial, International Journal of Geriatric Psychiatry, 11:1-7, 1996.
36. Saxena S, Wang D, **Bystritsky A**, Baxter LR. Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder, J Clin Psychiatry, 57:7:303-306, 1996.
37. Maidenberg E, Chen E, Craske MG, Bohn PB, **Bystritsky A**. Specificity of attention bias in panic disorder and social phobia. Journal of Anxiety Disorders, 10:529-541, 1996.
38. Small G, Birkett, M, Meyers BS, Koran LM, **Bystritsky A**, Nemeroff CB. Impact of physical illness on quality of life and antidepressant response in geriatric major depression, J Am Geriatr Soc, 44:10:1220-1225, 1996.
39. **Bystritsky A**, Strusser B. Treatment of obsessive-compulsive cutting behavior with naltrexone, J Clin Psychiatry, 57:423-424, 1996.

40. Ackerman DL, Greenland S, **Bystritsky A**, Katz RJ. Relationship between early side effects and therapeutic effects of clomopramine therapy in obsessive-compulsive disorder, J Clin Psychopharmacol, 16:324-328, 1996.
41. **Bystritsky A**, Vapnik T. Treatment of dysmorphophobia using videotape exposure, Depression and Anxiety, 5:1:39-41, 1997.
42. March JS et al., (**Bystritsky**, member of panel). The expert consensus panel report for obsessive-compulsive disorder, J Clin Psychiatry, 58(Suppl 4), 1997.
43. Schneider LS, Small GW, Hamilton SH, **Bystritsky A**, Nemeroff CB, Meyers BS. Estrogen replacement and response to fluoxetine in a multicenter geriatric depression trial: Fluoxetine collaborative study group, American Journal of Geriatric Psychiatry, 5(2):97-106, 1997.
44. Ackerman DL, Greenland S, **Bystritsky A**, Small GW. Characteristics of fluoxetine vs. placebo responders in a randomized trial of geriatric depression, Psychopharmacol Bull, 33:4:707-714, 1998.
45. Roy-Byrne P, Stein M, **Bystritsky A**, Katon W. Pharmacotherapy of panic disorder: Proposed guidelines for the family physician, J Am Board of Fam Pract, 11: 282-90, 1998.
46. **Bystritsky A**, Vapnik T, Leuchter A. Computerized EEG abnormalities in non-medicated panic patients, J Nerv Ment Dis, 187:2:113-114, 1999.
47. **Bystritsky A**, Saxena S, Maidment K, Vapnik T, Tarlow G, Rosen R. Quality of life changes in treatment-resistant OCD, Psychiatr Serv, 50:3:412-413, 1999.
48. Kronig MH, Apter J, Asnis G, **Bystritsky A**, Curtis G, Ferguson J, Landbloom R, Munjack D, Riesenbergr R, Robinson D, et al. Placebo-controlled, multicenter study of sertraline treatment for obsessive-compulsive disorder, J Clin Psychopharmacol, 19(2):172, 1999.
49. Foa EB, Davidson JRT, Frances A, Expert Group (**Bystritsky**, member). Expert consensus guideline for the treatment of post traumatic stress disorder, J Clin Psychiatry, Supplement 16, 1999.
50. Roy-Byrne PP, Stein MB, Russo J, Mercier E, Thomas R, McQuaid J, Katon W, Craske MG, **Bystritsky A**, Sherbourne C. Panic disorder in the primary care setting: Comorbidity, disability, service utilization and treatment, J Clin Psychiatry, 60:492-499, 1999.
51. Stein MB, Roy-Byrne PP, McQuaid JR, Laffaye C, Russo J, McCahill ME, Katon W, Craske MG, **Bystritsky A**, Sherbourne CD. Development of a brief diagnostic screen in panic disorder in primary care, Psychosom Med, 61:359-364, 1999.

52. Ackerman DL, Greenland S, **Bystritsky A**. Side effects as predictors of drug response in obsessive-compulsive disorder, J Clin Psychopharmacol, 19(5):459-65, 1999.
53. **Bystritsky A**, Rosen R, Suri R, Vapnik T. Pilot open-label study of nefazodone in panic disorder, Depress Anxiety, 10(3):137-9, 1999.
54. **Bystritsky A**, Vapnik T, Maidment K, Pynoos RS, Steinberg AM. Acute responses of anxiety disorder patients after a natural disaster, Depress Anxiety, 11(1):43 -4, 2000.
55. **Bystritsky A**, Craske M, Maidenberg E, Shapiro D. Autonomic reactivity of panic patients during a CO₂ inhalation procedure, Depress Anxiety, 11(1):15-26, 2000.
56. **Bystritsky A**, Craske M, Maidenberg E, Shapiro D. Autonomic reactivity in panic patients during structured psychophysiological assessment, Depress Anxiety, 2(2):102-8, 2000.
57. Ackerman DL, Greenland S, **Bystritsky A**, Small GW. Side effects and time course of response in a placebo-controlled trial of fluoxetine for the treatment of geriatric depression, J Clin Psychopharmacol, 20(6):658-65, 2000.
58. Saxena S, Winograd A, Dunkin JJ, Maidment K, Rosen R, Vapnik T, Tarlow G, **Bystritsky A**. A retrospective review of clinical characteristics and treatment response in body dysmorphic disorder versus obsessive-compulsive disorder, J Clin Psychiatry, 62(1):67-72, 2001.
59. **Bystritsky A**, Liberman RP, Hwang S, Wallace CJ, Vapnik T, Maidment K, Saxena S. Social functioning and quality of life comparisons between obsessive-compulsive and schizophrenic disorders, Depress Anxiety, 14(4):214-8, 2001.
60. **Bystritsky A**, Pontillo D, Powers M, Sabb FW, Craske MG, Bookheimer SY. Functional MRI changes during panic anticipation and imagery exposure, Neuroreport, Dec 21;12(18):3953-7, 2001.
61. Klein DF, Thase M, Endicott J, Adler L, Glick I, Kalali A, Levanter S, Mattes J, Ross P, **Bystritsky A**. Improving clinical trials: American society of clinical psychopharmacology recommendations, Arch Gen Psychiatry, Mar;59(3):272-8, 2002.
62. Craske MC, Lang AJ, Rowe M, DeCola JP, Simmons J, Mann C, Yan-Go F, **Bystritsky A**. Pre-sleep attributions about arousal during sleep: Nocturnal panic, J Abnorm Psychol, Feb;111(1):53-62, 2002.
63. Saxena S, Maidment KM, Rosen R, Vapnik T, Tarlow G, **Bystritsky A**. Obsessive-compulsive hoarding: symptom severity and response to multi-modal treatment, J Clin Psychiatry, Jan;63(1):21-7, 2002.

64. Hazlett-Stevens H, Craske MG, Roy-Byrne PP, Sherbourne CD, Stein MB, **Bystritsky A**. Predictors of willingness to consider medication and psychosocial treatment for panic disorder in primary care patients, Gen Hosp Psychiatry, Sep-Oct;24(5):316-21, 2002.
65. Craske MG, Roy-Byrne P, Stein MB, Donald-Sherbourne C, **Bystritsky A**, Katon W, Sullivan G. Treating panic disorder in primary care: a collaborative care intervention, Gen Hosp Psychiatry, May-Jun;24(3):148-55, 2002.
66. Craske MG, Lang AJ, Mystkowski JL, Zucker BG, **Bystritsky A**, Yan-Go F. Does nocturnal panic represent a more severe form of panic disorder?, J Nerv Ment Dis, Sep;190(9):611-8, 2002.
67. **Bystritsky A**. Anxiety Disorders: Alternative Treatment Strategies, Primary Psychiatry, Jul; 202:8-10, 2002.
68. Roy-Byrne PP, Sherbourne CD, Craske MG, Stein MB, Katon WJ, Sullivan G, Means A, **Bystritsky A**. Moving treatment research from clinical trials to the real world, Psychiatric Services, 54:327-332, 2003.
69. Roy-Byrne P, Russo J, Pollack M, Steward R, **Bystritsky A**, Bell J, Rosenbaum J, Corrigan MH, Stolk J, Rush AJ, Ballenger J. Personality and symptom sensitivity predictors of alprazolam withdrawal in panic disorder, Psychological Medicine, 33:1-8, 2003.
70. Means-Christensen A, Sherbourne CD, Roy-Byrne P, Craske MG, **Bystritsky A**, Stein MB. The Composite International Diagnostic Interview (CIDI-Auto): problems and remedies for diagnosing panic disorder and social phobia, International Journal of Methods in Psychiatric Research, 12:167-181, 2003.
71. **Bystritsky A**. Diagnosis and Treatment of Anxiety, Focus Publications, Vol II, 3:333-343, 2004.
72. **Bystritsky A**. Current Pharmacological Treatments for Obsessive-Compulsive Disorder, Essential Psychopharmacology, 5(4):251-272, 2004.
73. Stein MB, Sherbourne CD, Craske MG, Means-Christensen A, **Bystritsky A**, Katon W, Sullivan G, Roy-Byrne PP. Quality of care for primary care patients with anxiety disorders, Am J Psychiatry, Dec;161(12):2230-7, 2004.
74. **Bystritsky A**, Ackerman DL, Rosen RM, Vapnik T, Gorbis E, Maidment KM, Saxena S. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial. J Clin Psychiatry. Apr;65(4):565-8, 2004.
75. Stein MB, Sherbourne CD, Craske MG, Means-Christensen A, **Bystritsky A**, Katon W, Sullivan G, Roy-Byrne PP. Quality of care for primary care patients with anxiety disorders, Am J Psychiatry, Dec;161(12):2230-7, 2004.

76. **Bystritsky A.** Anxiety Disorders: Diagnosis, Dimensions, and Process, Primary Psychiatry, Nov;12(11):33-34, 2005.
77. Feusner J, Cameron M, **Bystritsky A.** Pharmacotherapy and Psychotherapy for Panic Disorder, Primary Psychiatry, Nov;12:49-55, 2005.
78. Stein MB, Pollack MH, **Bystritsky A**, Kelsey JE, Mangano RM. Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial, Psychopharmacology (Berl), Jan;177(3):280-8, 2005.
79. Bogan AM, Koran LM, Chuong HW, Vapnik T, **Bystritsky A.** Quetiapine augmentation in obsessive-compulsive disorder resistant to serotonin reuptake inhibitors: an open-label study, J Clin Psychiatry, Jan;66(1):73-9, 2005.
80. Roy-Byrne PP, Craske MG, Stein MB, Sullivan G, **Bystritsky A**, Katon W, Golinelli D, Sherbourne CD. A randomized effectiveness trial of cognitive-behavioral therapy and medication for primary care panic disorder, Arch Gen Psychiatry, Mar;62(3):290-8, 2005.
81. Roy-Byrne PP, **Bystritsky A**, Russo J, Craske MG, Sherbourne CD, Stein MB. Use of herbal medicine in primary care patients with mood and anxiety disorders, Psychosomatics, Mar-Apr;46(2):117-22, 2005.
82. Wagner AW, **Bystritsky A**, Russo JE, Craske MG, Sherbourne CD, Stein MB, Roy-Byrne PP. Beliefs about psychotropic medication and psychotherapy among primary care patients with anxiety disorders, Depress Anxiety, 21(3):99-105, 2005.
83. Craske MG, Edlund MJ, Sullivan G, Roy-Byrne P, Sherbourne C, **Bystritsky A**, Stein MB. Perceived unmet need for mental health treatment and barriers to care among patients with panic disorder, Psychiatr Serv, Aug;56(8):988-94, 2005.
84. **Bystritsky A**, Wagner AW, Russo JE, Stein MB, Sherbourne CD, Craske MG, Roy-Byrne PP. Assessment of beliefs about psychotropic medication and psychotherapy: development of a measure for patients with anxiety disorders, Gen Hosp Psychiatry, Sep-Oct;27(5):313-8, 2005.
85. **Bystritsky A.** Diagnosis and Treatment of Anxiety (in Russian), Bridging Eastern and Western Psychiatry, III(2):1-11, 2005.
86. Kobak KA, Taylor LV, **Bystritsky A**, Kohlenberg CJ, Greist JH, Tucker P, Warner G, Futterer R, Vapnik T. St John's Wort versus placebo in obsessive-compulsive disorder: results from a double-blind study, Int Clin Psychopharmacol, Nov;20(6):299-304, 2005.
87. Craske MG, Golinelli D, Stein MB, Roy-Byrne P, **Bystritsky A**, Sherbourne C. Does the addition of cognitive behavioral therapy improve panic disorder treatment outcome relative to medication alone in the primary-care setting?, Psychol Med, Nov;35(11):1645-54, 2005. Stein MB, Roy-

Byrne PP, Craske MG, **Bystritsky A**, Sullivan G, Pyne JM, Katon W, Sherbourne CD. Functional impact and health utility of anxiety disorders in primary care outpatients, Med Care, Dec;43(12):1164-70, 2005.

88. Bystritsky A. Anxiety Disorders: Diagnosis, Dimensions and Process, Primary Psychiatry, Nov; 12 (11) 33-34, 2005.

89. Feusner J, Cameron M, **Bystritsky A**. Pharmacotherapy and Psychotherapy for Panic Disorder, Primary Psychiatry, Nov; 12 (11) 33-34, 2005.

90. Bystritsky A, Wagner AW, Russo JE, Stein MB, Sherbourne CD, Craske MG, Roy-Byrne PP. Assessment of beliefs about psychotropic medication and psychotherapy: development of a measure for patients with anxiety disorders, Gen Hosp Psychiatry, Sep-Oct;27(5):313-8, 2005.

91. Bell S, Shipman M, **Bystritsky A**, Haifley T. Fluoxetine treatment and testosterone levels, Ann Clin Psychiatry, Jan-Mar;18(1):19-22, 2006.

92. Bystritsky A. Treatment-resistant anxiety disorders, Mol Psychiatry, Sep;11(9):805-14, 2006.

93. Bystritsky A, Zvartau EE, Neznanov NG. Differential Diagnosis of Panic Disorder (in Russian), Psychiatry and Medical Psychology, 3:16-20, 2006.

94. Craske MG, Roy-Byrne P, Stein MB, Sullivan G, Hazlett-Stevens H, **Bystritsky A**, Sherbourne C. CBT intensity and outcome for panic disorder in a primary care setting, Behav Ther, Jun;37(2):112-9, 2006.

95. Sullivan G, Craske MG, Sherbourne C, Edlund MJ, Rose RD, Golinelli D, Chavira DA, **Bystritsky A**, Stein MB, Roy-Byrne PP. Design of the Coordinated Anxiety Learning and Management (CALM) study: innovations in collaborative care for anxiety disorders, Gen Hosp Psychiatry, Sep-Oct;29(5):379-387, 2007.

96. Feusner JD, Townsend J, **Bystritsky A**, Bookheimer S. Visual Information Processing of Faces in Body Dysmorphic Disorder, Arch Gen Psychiatry. 2007 Dec;64(12):1417-25.

98. Bystritsky A, Kerwin L, Feusner JD. A pilot study of Rhodiola rosea (Rhodax) for generalized anxiety disorder (GAD). J Altern Complement Med. 2008 Mar;14(2):175-80.

99. Bystritsky A, Kerwin L, Feusner J. A pilot study of cranial electrotherapy stimulation for generalized anxiety disorder. J Clin Psychiatry. 2008 Mar;69(3):412-7.

100. Bystritsky A, Kerwin L, Feusner JD, Vapnik T. A Pilot Controlled Trial of Bupropion XL Versus Escitalopram in Generalized Anxiety Disorder. Psychopharmacol Bull. 2008;41(1):46-51.

101. Campbell-Sills L, Norman SB, Craske MG, Sullivan G, Lang AJ, Chavira DA,

- Bystritsky A**, Sherbourne C, Roy-Byrne P, Stein MB. Validation of a brief measure of anxiety-related severity and impairment: the Overall Anxiety Severity and Impairment Scale (OASIS). J Affect Disord. 2009 Jan;112(1-3):92-101.
102. Powers MB, Smits JA, Whitley D, **Bystritsky A**, Telch MJ. The effect of attributional processes concerning medication taking on return of fear. J Consult Clin Psychol. 2008 Jun;76(3):478-90.
103. **Bystritsky A**, Kaplan JT, Feusner JD, Kerwin LE, Wadekar M, Burock M, Wu AD, Iacoboni M. A preliminary study of fMRI-guided rTMS in the treatment of generalized anxiety disorder. J Clin Psychiatry. 2008 Jul;69(7):1092-8.
104. Feusner JD, Kerwin L, Saxena S, **Bystritsky A**. Differential Efficacy of Memantine for Obsessive-Compulsive Disorder vs. Generalized Anxiety Disorder: An Open-Label Trial. Psychopharmacol Bull. 2009;42(1):81-93.
105. Craske MG, Rose RD, Lang A, Welch SS, Campbell-Sills L, Sullivan G, Sherbourne C, **Bystritsky A**, Stein MB, Roy-Byrne PP. Computer-assisted delivery of cognitive behavioral therapy for anxiety disorders in primary-care settings. Depress Anxiety. 2009;26(3):235-42.
106. Roy-Byrne P, Veitengruber JP, **Bystritsky A**, Edlund MJ, Sullivan G, Craske MG, Welch SS, Rose R, Stein MB. Brief intervention for anxiety in primary care patients. J Am Board Fam Med. 2009 Mar-Apr;22(2):175-86.
107. **Bystritsky A**, Kerwin LE, Feusner JD. A preliminary study of fMRI-guided rTMS in the treatment of generalized anxiety disorder: 6-month follow-up. J Clin Psychiatry. 2009 Mar;70(3):431-2.
108. Feusner JD, Townsend J, **Bystritsky A**, McKinley M, Moller H, Bookheimer S. Regional brain volumes and symptom severity in body dysmorphic disorder. Psychiatry Res. 2009 May 15;172(2):161-7.
109. Craske MG, Roy-Byrne PP, Stein MB, Sullivan G, Sherbourne C, **Bystritsky A**. Treatment for anxiety disorders: Efficacy to effectiveness to implementation. Behav Res Ther. 2009 Nov;47(11):931-7.
110. Chavira DA, Stein MB, Golinelli D, Sherbourne CD, Craske MG, Sullivan G, **Bystritsky A**, Roy-Byrne PP. Predictors of clinical improvement in a randomized effectiveness trial for primary care patients with panic disorder. J Nerv Ment Dis. 2009 Oct;197(10):715-21.
111. **Bystritsky A**, Kerwin L, Niv N, Natoli JL, Abrahami N, Klap R, Wells K, Young AS. Clinical and subthreshold panic disorder. Depress Anxiety. 2010 Apr;27(4):381-9.
112. Sherbourne CD, Sullivan G, Craske MG, Roy-Byrne P, Golinelli D, Rose RD, Chavira DA, **Bystritsky A**, Stein MB. Functioning and disability levels in primary

care out-patients with one or more anxiety disorders. Psychol Med. 2010 Feb 11:1-10.

113. Roy-Byrne P, Craske MG, Sullivan G, Rose RD, Edlund MJ, Lang AJ, **Bystritsky A**, Welch SS, Chavira DA, Golinelli D, Campbell-Sills L, Sherbourne CD, Stein MB. Delivery of evidence-based treatment for multiple anxiety disorders in primary care: a randomized controlled trial. JAMA. 2010 May 19;303(19):1921-8.
114. Feusner JD, **Bystritsky A**, Helleman G, Bookheimer S. Impaired identity recognition of faces with emotional expressions in body dysmorphic disorder. Psychiatry Res. 2010 May 19.
115. Saxena S, Ayers CR, Maidment KM, Vapnik T, Wetherell JL, **Bystritsky A**. Quality of life and functional impairment in compulsive hoarding. J Psychiatr Res. 2011 Apr;45(4):475-80. Epub 2010 Sep 6.
116. Rabinovich MI, Muezzinoglu MK, Strigo I, **Bystritsky A**. Dynamical principles of emotion-cognition interaction: mathematical images of mental disorders. PLoS One. 2010 Sep 21;5(9):e12547.
117. Yoo SS, **Bystritsky A**, Lee JH, Zhang Y, Fischer K, Min BK, McDannold NJ, Pascual-Leone A, Jolesz FA. Focused ultrasound modulates region-specific brain activity. Neuroimage. 2011 Feb 24
118. Stein MB, Roy-Byrne PP, Craske MG, Campbell-Sills L, Lang AJ, Golinelli D, Rose RD, **Bystritsky A**, Sullivan G, Sherbourne CD. Quality of and patient satisfaction with primary health care for anxiety disorders. J Clin Psychiatry. 2011 Feb 22.
119. Min BK, **Bystritsky A**, Jung KI, Fischer K, Zhang Y, Maeng LS, In Park S, Chung YA, Jolesz FA, Yoo SS. Focused ultrasound-mediated suppression of chemically-induced acute epileptic EEG activity. BMC Neurosci. 2011 Mar 6;12:23.
120. Craske MG, Stein MB, Sullivan G, Sherbourne C, **Bystritsky A**, Rose RD, Lang AJ, Welch S, Campbell-Sills L, Golinelli D, Roy-Byrne P. Disorder-specific impact of coordinated anxiety learning and management treatment for anxiety disorders in primary care. Arch Gen Psychiatry. 2011 Apr;68(4):378-88
121. Rapgay L, **Bystritsky A**, Dafer RE, Spearman M. New Strategies for Combining Mindfulness with Integrative Cognitive Behavioral Therapy for the Treatment of Generalized Anxiety Disorder. J Ration Emot Cogn Behav Ther. 2011 Jun;29(2):92-119. Epub 2009 Jun 10.
122. Rose RD, Lang AJ, Welch SS, Campbell-Sills L, Chavira DA, Sullivan G, Sherbourne C, **Bystritsky A**, Stein MB, Roy-Byrne PP, Craske MG. Training primary care staff to deliver a computer-assisted cognitive-behavioral therapy program for anxiety disorders. Gen Hosp Psychiatry. 2011 Jul-Aug;33(4):336-42. Epub 2011 Jun 8.

123. **Bystritsky A**, Korb AS, Douglas PK, Cohen MS, Melega WP, Mulgaonkar AP, DeSalles A, Min BK, Yoo SS. A review of low-intensity focused ultrasound pulsation. *Brain Stimul.* 2011 Jul;4(3):125-36. Epub 2011 Apr 1.
124. Shiovitz TM, Zarrow ME, Shiovitz AM, **Bystritsky A**. Failure rate and "professional subjects" in clinical trials of major depressive disorder. *J Clin Psychiatry.* 2011 Sep;72(9):1284.
125. Mulgaonkar AP, Singh RS, Babakhanian M, Culjat MO, Grundfest WS, Gorgulho A, Lacan G, De Salles AA, **Bystritsky A**, Melega WP. A prototype stimulator system for noninvasive low intensity focused ultrasound delivery. *Stud Health Technol Inform.* 2012;173:297-303.
126. **Bystritsky A**, Nierenberg AA, Feusner JD, Rabinovich M. Computational non-linear dynamical psychiatry: a new methodological paradigm for diagnosis and course of illness. *J Psychiatr Res.* 2012 Apr;46(4):428-35. Epub 2012 Jan 18. Review.
127. **Bystritsky A**, Hovav S, Sherbourne C, Stein MB, Rose RD, Campbell-Sills L, Golinelli D, Sullivan G, Craske MG, Roy-Byrne PP. Use of complementary and alternative medicine in a large sample of anxiety patients. *Psychosomatics.* 2012 May;53(3):266-72. Epub 2012 Feb 1.
128. Feusner JD, Madsen S, Moody TD, Bohon C, Hembacher E, Bookheimer SY, **Bystritsky A**. Effects of cranial electrotherapy stimulation on resting state brain activity. *Brain Behav.* 2012 May;2(3):211-20.
129. Lang AJ, Wilkins K, Roy-Byrne PP, Golinelli D, Chavira D, Sherbourne C, Rose RD, **Bystritsky A**, Sullivan G, Craske MG, Stein MB. Abbreviated PTSD Checklist (PCL) as a guide to clinical response. *Gen Hosp Psychiatry.* 2012 Jul-Aug;34(4):332-8. Epub 2012 Mar 27.
130. Sullivan G, Sherbourne C, Chavira DA, Craske MG, Gollineli D, Han X, Rose RD, **Bystritsky A**, Stein MB, Roy-Byrne P, Stein MB, Roy-Byrne P. Does a quality improvement intervention for anxiety result in differential outcomes for lower income patients?. *Am J Psychiatry.* 2013 Feb;170(2):218-25. doi: 10.1176/appi.ajp.2012.12030375
131. Niles AN, Sherbourne CD, Roy-Byrne PP, Stein MB, Sullivan G, **Bystritsky A**, Craske MG. Anxiety treatment improves physical functioning with oblique scoring of the SF-12 Short Form Health Survey. *Gen Hosp Psychiatry.* 2013 Jan 16. doi: 10.1016/j.genhosppsych.2012.12.004.
132. Campbell-Sills L, Sherbourne CD, Roy-Byrne P, Craske MG, Sullivan G, **Bystritsky A**, Lang AJ, Chavira DA, Rose RD, Shaw Welch S, Stein MB. Effects of co-occurring depression on treatment for anxiety disorders: analysis of outcomes from a large primary care effectiveness trial. *J Clin Psychiatry.* 2012 Dec;73(12):1509-16. doi: 10.4088/JCP
133. Brown LA, Craske MG, Glenn DE, Stein MB, Sullivan G, Sherbourne C, **Bystritsky A**, Welch SS, Campbell-Sills L, Lang A, Roy-Byrne P, Rose RD. CBT competence in novice therapists improves anxiety outcomes. *Depress Anxiety.* 2013 Feb;30(2):97-115. doi: 10.1002/da.22027.

134. **Bystritsky A**, Khalsa SS, Cameron ME, Schiffman J. Current diagnosis and treatment of anxiety disorders. *Journal of Clinical Pharmacy and Therapeutics*, 2013 Jan;38(1):30-57.
135. Bomyea J, Lang A, Craske MG, Chavira DA, Sherbourne CD, Rose RD, Golinelli D, Campbell-Sills L, Welch SS, Sullivan G, **Bystritsky A**, Roy-Byrne P, Stein MB. Course of symptom change during anxiety treatment: Reductions in anxiety and depression in patients completing the Coordinated Anxiety Learning and Management program. *Psychiatry Res*. 2015 Sep 30;229(1-2):133-42.
136. Levkovitz Y, Isserles M, Padberg F, Lisanby SH, **Bystritsky A**, Xia G, Tendler A, Daskalakis ZJ, Winston JL, Dannon P, Hafez HM, Reti IM, Morales OG, Schlaepfer TE, Hollander E, Berman JA, Husain MM, Sofer U, Stein A, Adler S, Deutsch L, Deutsch F, Roth Y, George MS, Zangen A. Efficacy and safety of deep transcranial magnetic stimulation for major depression: a prospective multicenter randomized controlled trial. *World Psychiatry*. 2015 Feb;14(1):64-73.
137. Wolitzky-Taylor K, Brown LA, Roy-Byrne P, Sherbourne C, Stein MB, Sullivan G, **Bystritsky A**, Craske MG. The impact of alcohol use severity on anxiety treatment outcomes in a large effectiveness trial in primary care. *J Anxiety Disord*. 2015 Mar;30:88-93
138. **Bystritsky A**, Kronemyer D. Stress and anxiety: counterpart elements of the stress/anxiety complex. *Psychiatr Clin North Am*. 2014 Dec;37(4):489-518
139. Brown LA, Krull JL, Roy-Byrne P, Sherbourne CD, Stein MB, Sullivan G, Rose RD, **Bystritsky A**, Craske MG. An examination of the bidirectional relationship between functioning and symptom levels in patients with anxiety disorders in the CALM study. *Psychol Med*. 2015 Feb;45(3):647-61.
140. Kronemyer D, **Bystritsky A**. A non-linear dynamical approach to belief revision in cognitive behavioral therapy. *Front Comput Neurosci*. 2014 May 15;8:55.
141. Chavira DA, Golinelli D, Sherbourne C, Stein MB, Sullivan G, **Bystritsky A**, Rose RD, Lang AJ, Campbell-Sills L, Welch S, Bumgardner K, Glenn D, Barrios V, Roy-Byrne P, Craske M. Treatment engagement and response to CBT among Latinos with anxiety disorders in primary care. *J Consult Clin Psychol*. 2014 Jun;82(3):392-403.
142. Brown LA, Wiley JF, Wolitzky-Taylor K, Roy-Byrne P, Sherbourne C, Stein MB, Sullivan G, Rose RD, **Bystritsky A**, Craske MG. Changes in self-efficacy and outcome expectancy as predictors of anxiety outcomes from the CALM study. *Depress Anxiety*. 2014 Aug;31(8):678-89.
143. **Bystritsky A**, Danial J, Kronemyer D. Interactions between diabetes and anxiety

and depression: implications for treatment. *Endocrinol Metab Clin North Am*. 2014 Mar;43(1):269-83.

144. Khalsa SS, Shahabi L, Ajijola OA, **Bystritsky A**, Naliboff BD, Shivkumar K. Synergistic application of cardiac sympathetic decentralization and comprehensive psychiatric treatment in the management of anxiety and electrical storm. *Front Integr Neurosci*. 2014 Jan 2;7:98.
145. Dour HJ, Wiley JF, Roy-Byrne P, Stein MB, Sullivan G, Sherbourne CD, **Bystritsky A**, Rose RD, Craske MG. Perceived social support mediates anxiety and depressive symptom changes following primary care intervention. *Depress Anxiety*. 2014 May;31(5):436-42. doi: 10.1002/da.22216. Epub 2013 Dec 12. PubMed PMID: 24338947; PubMed Central PMCID: PMC4136523.
146. **Bystritsky A**, Korb A.S. A Review of Low Intensity Transcranial Focused Ultrasound for Clinical Applications. *Curr Behav Neurosci Rep* (2015) 2:60–66
147. Wolitzky-Taylor K, Brown LA, Roy-Byrne P, Sherbourne C, Stein MB, Sullivan G, **Bystritsky A**, Craske MG. The impact of alcohol use severity on anxiety treatment outcomes in a large effectiveness trial in primary care. *J Anxiety Disord*. 2015 Mar;30:88-93.
148. **Bystritsky A**, Kronemyer D. Stress and anxiety: counterpart elements of the stress/anxiety complex. *Psychiatr Clin North Am*. 2014 Dec;37(4):489-518.
149. Levkovitz Y, Isserles M, Padberg F, Lisanby SH, **Bystritsky A**, Xia G, Tendler A, Daskalakis ZJ, Winston JL, Dannon P, Hafez HM, Reti IM, Morales OG, Schlaepfer TE, Hollander E, Berman JA, Husain MM, Sofer U, Stein A, Adler S, Deutsch L, Deutsch F, Roth Y, George MS, Zangen A. Efficacy and safety of deep transcranial magnetic stimulation for major depression: a prospective multicenter randomized controlled trial. *World Psychiatry*. 2015 Feb;14(1):64-73.
150. Bomyea J, Lang A, Craske MG, Chavira DA, Sherbourne CD, Rose RD, Golinelli D, Campbell-Sills L, Welch SS, Sullivan G, **Bystritsky A**, Roy-Byrne P, Stein MB. Course of symptom change during anxiety treatment: Reductions in anxiety and depression in patients completing the Coordinated Anxiety Learning and Management program. *Psychiatry Res*. 2015 Sep 30;229(1-2):133-42
151. Monti MM, Schnakers C, Korb AS, **Bystritsky A**, Vespa PM. Non-Invasive Ultrasonic Thalamic Stimulation in Disorders of Consciousness after Severe Brain Injury: A First-in-Man Report. *Brain Stimul*. 2016 Nov - Dec;9(6):940-941
152. Campbell-Sills L, Roy-Byrne PP, Craske MG, **Bystritsky A**, Sullivan G, Stein MB. Improving outcomes for patients with medication-resistant anxiety: effects of collaborative care with cognitive behavioral therapy. *Depress Anxiety*. 2016

Dec;33(12):1099-1106.

153. Niles AN, Loerinc AG, Krull JL, Roy-Byrne P, Sullivan G, Sherbourne CD, **Bystritsky A**, Craske MG. Advancing Personalized Medicine: Application of a Novel Statistical Method to Identify Treatment Moderators in the Coordinated Anxiety Learning and Management Study. *Behav Ther*. 2017 Jul;48(4):490-500.
154. Petkus AJ, Wetherell JL, Stein MB, Chavira DA, Craske MG, Sherbourne C, Sullivan G, **Bystritsky A**, Roy-Byrne P. Age Differences in Death and Suicidal Ideation in Anxious Primary Care Patients. *Clin Gerontol*. 2017 Jul 25:1-11.
155. Petkus AJ, Wetherell JL, Stein MB, Chavira DA, Craske MG, Sherbourne C, Sullivan G, **Bystritsky A**, Roy-Byrne P. Age Differences in Death and Suicidal Ideation in Anxious Primary Care Patients. *Clin Gerontol*. 2018 Jul-Sep;41(4):271-281. doi: 10.1080/07317115.2017.1356893. 2017 Sep 29. PMID: 28960158
156. Escovar EL, Craske M, Roy-Byrne P, Stein MB, Sullivan G, Sherbourne CD, **Bystritsky A**, Chavira DA. Cultural influences on mental health symptoms in a primary care sample of Latinx patients. *J Anxiety Disord*. 2018 Apr;55:39-47. doi: 10.1016/j.janxdis.2018.03.005. 2018 Mar 12. PMID: 29576380
157. Nicodemus NE, Becerra S, Kuhn TP, Packham HR, Duncan J, Mahdavi K, Iovine J, Kesari S, Pereles S, Whitney M, Mamoun M, Franc D, **Bystritsky A**, Jordan S. Focused transcranial ultrasound for treatment of neurodegenerative dementia. *Alzheimers Dement (N Y)*. 2019 Aug 8;5:374-381. doi: 10.1016/j.trci.2019.06.007. eCollection 2019. PMID: 31440580
158. Carmi L, Tendler A, **Bystritsky A**, Hollander E, Blumberger DM, Daskalakis J, Ward H, Lapidus K, Goodman W, Casuto L, Feifel D, Barnea-Ygaël N, Roth Y, Zangen A, Zohar J. Efficacy and Safety of Deep Transcranial Magnetic Stimulation for Obsessive-Compulsive Disorder: A Prospective Multicenter Randomized Double-Blind Placebo-Controlled Trial. *Am J Psychiatry*. 2019 Nov 1;176(11):931-938. doi: 10.1176/appi.ajp.2019.18101180. Epub 2019 May 21. PMID: 31109199 Clinical Trial.
159. Spivak NM, Schafer ME, **Bystritsky A**. Reversible neuroinhibition does not require a thermal mechanism. *Brain Stimul*. 2020 Jan-Feb;13(1):262. doi: 10.1016/j.brs.2019.09.007. Epub 2019 Sep 24. PMID: 31582302 .
160. Badran BW, Caulfield KA, Stomberg-Firestein S, Summers PM, Dowdle LT, Savoca M, Li X, Austelle CW, Short EB, Borckardt JJ, Spivak N, **Bystritsky A**, George MS. Sonication of the anterior thalamus with MRI-Guided transcranial focused ultrasound (tFUS) alters pain thresholds in healthy adults: A double-blind, sham-controlled study. *Brain Stimul*. 2020 Nov-Dec;13(6):1805-1812. doi: 10.1016/j.brs.2020.10.007. Epub 2020 Oct 24. PMID: 33127579
161. Schafer ME, Spivak NM, Korb AS, **Bystritsky A**. Design, Development, and Operation of a Low-Intensity Focused Ultrasound Pulsation (LIFUP) System for Clinical Use. *IEEE Trans Ultrason*

Ferroelectr Freq Control. 2021 Jan;68(1):54-64. doi: 10.1109/TUFFC.2020.3006781. Epub 2020 Dec 23. PMID: 32746201

- 162. Bystritsky A**, Spivak NM, Dang BH, Becerra SA, Distler MG, Jordan SE, Kuhn TP. Brain circuitry underlying the ABC model of anxiety. *J Psychiatr Res*. 2021 Jun;138:3-14. doi: 10.1016/j.jpsychires.2021.03.030. Epub 2021 Mar 25. PMID: 33798786
- 163.** Mahdavi KD, Jordan SE, Barrows HR, Pravdic M, Habelhah B, Evans NE, Blades RB, Iovine JJ, Becerra SA, Steiner RA, Chang M, Kesari S, **Bystritsky A**, O'Connor E, Gross H, Pereles FS, Whitney M, Kuhn T. Treatment of Dementia With Bosutinib: An Open-Label Study of a Tyrosine Kinase Inhibitor. *Neurol Clin Pract*. 2021 Jun;11(3):e294-e302. doi: 10.1212/CPJ.0000000000000918. PMID: 34484904
- 164.** Stern JM, Spivak NM, Becerra SA, Kuhn TP, Korb AS, Kronemyer D, Khanlou N, Reyes SD, Monti MM, Schnakers C, Walshaw P, Keselman I, Cohen MS, Yong W, Fried I, Jordan SE, Schafer ME, Engel J Jr, **Bystritsky A**. Safety of focused ultrasound neuromodulation in humans with temporal lobe epilepsy. *Brain Stimul*. 2021 Jul-Aug;14(4):1022-1031. doi: 10.1016/j.brs.2021.06.003. Epub 2021 Jun 23. PMID: 34198105
- 165.** Kuhn T, Becerra S, Duncan J, Spivak N, Dang BH, Habelhah B, Mahdavi KD, Mamoun M, Whitney M, Pereles FS, **Bystritsky A**, Jordan SE. Translating state-of-the-art brain magnetic resonance imaging (MRI) techniques into clinical practice: multimodal MRI differentiates dementia subtypes in a traditional clinical setting. *Quant Imaging Med Surg*. 2021 Sep;11(9):4056-4073. doi: 10.21037/qims-20-1355. PMID: 34476189
- 166.** Zangen A, Moshe H, Martinez D, Barnea-Ygaël N, Vapnik T, Bystritsky A, Duffy W, Toder D, Casuto L, Grosz ML, Nunes EV, Ward H, Tendler A, Feifel D, Morales O, Roth Y, Iosifescu DV, Winston J, Wirecki T, Stein A, Deutsch F, Li X, George MS. Repetitive transcranial magnetic stimulation for smoking cessation: a pivotal multicenter double-blind randomized controlled trial. *World Psychiatry*. 2021 Oct;20(3):397-404. doi: 10.1002/wps.20905. PMID: 34505368
- 167.** Haroon J, Mahdavi K, Zielinski MA, Habelhah B, Chan L, **Bystritsky A**, Kuhn T, Becerra S, Jordan S. A case of COVID-encephalopathy imaged with fMRI and treated with near infrared light. *Brain Stimul*. 2021 Nov-Dec;14(6):1444-1446. doi: 10.1016/j.brs.2021.09.005. Epub 2021 Sep 21. PMID: 34560318
- 168.** Isserles M, Tendler A, Roth Y, **Bystritsky A**, Blumberger DM, Ward H, Feifel D, Viner L, Duffy W, Zohar J, Keller CJ, Bhati MT, Etkin A, George MS, Filipic I, Lapidus K, Casuto L, Vaishnavi S, Stein A, Deutsch L, Deutsch F, Morales O, Daskalakis ZJ, Zangen A, Ressler KJ. Deep Transcranial Magnetic Stimulation Combined With Brief Exposure for Posttraumatic Stress Disorder: A Prospective Multisite Randomized Trial. *Biol Psychiatry*. 2021 Nov 15;90(10):721-728. doi: 10.1016/j.biopsych.2021.04.019. Epub 2021 May 4. PMID: 34274108 Clinical Trial.
- 169.** Spivak NM, Korb AS, Reyes SD, Bych BP, Schafer SF, Khanlou N, Johnson EA, Schafer ME, Cohen MS, Kuhn T, **Bystritsky A**. Histological examination of focused ultrasound effects on human

- brain tissue. *Brain Stimul.* 2021 Nov-Dec;14(6):1486-1488. doi: 10.1016/j.brs.2021.09.015. Epub 2021 Oct 1. PMID: 34607066
170. Bystritsky A. Novel Neurotherapeutics. *Focus (Am Psychiatr Publ)*. 2022 Jan;20(1):1-2. doi: 10.1176/appi.focus.20210032. Epub 2022 Jan 25. PMID: 35746929
171. Badran BW, Caulfield KA, Stomberg-Firestein S, Summers PM, Dowdle LT, Savoca M, Li X, Austelle CW, Short EB, Borckardt JJ, Spivak N, **Bystritsky A**, George MS. Sonication of the Anterior Thalamus With MRI-Guided Transcranial Focused Ultrasound (tFUS) Alters Pain Thresholds in Healthy Adults: A Double-Blind, Sham-Controlled Study. *Focus (Am Psychiatr Publ)*. 2022 Jan;20(1):90-99. doi: 10.1176/appi.focus.20109. Epub 2022 Jan 25. PMID: 35746940.
172. Carmi L, Tendler A, **Bystritsky A**, Hollander E, Blumberger DM, Daskalakis J, Ward H, Lapidus K, Goodman W, Casuto L, Feifel D, Barnea-Ygaël N, Roth Y, Zangen A, Zohar J. Efficacy and Safety of Deep Transcranial Magnetic Stimulation for Obsessive-Compulsive Disorder: A Prospective Multicenter Randomized Double-Blind Placebo-Controlled Trial. *Focus (Am Psychiatr Publ)*. 2022 Jan;20(1):152-159. doi: 10.1176/appi.focus.20103. Epub 2022 Jan 25. PMID: 35746941
173. Dell'Italia J, Sanguinetti JL, Monti MM, Bystritsky A, Reggente N. Current State of Potential Mechanisms Supporting Low Intensity Focused Ultrasound for Neuromodulation. *Front Hum Neurosci.* 2022 Apr 25;16:872639. doi: 10.3389/fnhum.2022.872639. eCollection 2022. PMID: 35547195 Review.
174. Spivak NM, Haroon J, Swenson A, Turnbull SA, Dang N, Ganeles M, Price C, Distler M, Nurmi E, Lavretsky H, **Bystritsky A**. Microbiome in Anxiety and Other Psychiatric Disorders. *Med Clin North Am.* 2023 Jan;107(1):73-83. doi: 10.1016/j.mcna.2022.08.010. Epub 2022 Oct 28. PMID: 36402501 Review.
175. Zangen A, Zibman S, Tendler A, Barnea-Ygaël N, Alyagon U, Blumberger DM, Grammer G, Shalev H, Gulevski T, Vapnik T, **Bystritsky A**, Filipčić I, Feifel D, Stein A, Deutsch F, Roth Y, George MS. Pursuing personalized medicine for depression by targeting the lateral or medial prefrontal cortex with Deep TMS. *JCI Insight.* 2023 Feb 22;8(4):e165271. doi: 10.1172/jci.insight.165271. PMID: 36692954 Clinical Trial.
176. Escovar EL, Bocanegra ES, Craske MG, **Bystritsky A**, Roy-Byrne P, Sherbourne CD, Stein MB, Chavira DA. Mediators of Ethnic Differences in Dropout Rates From a Randomized Controlled Treatment Trial Among Latinx and Non-Latinx White Primary Care Patients With Anxiety Disorders. *J Nerv Ment Dis.* 2023 Jun 1;211(6):427-439. doi: 10.1097/NMD.0000000000001533. PMID: 37252881 Clinical Trial.
177. Surya JR, Habelhah B, Haroon J, Mahdavi K, Jordan K, Becerra S, Venkatraman V, Deveney C, **Bystritsky A**, Kuhn T, Jordan S. Functional MRI Lateralization [M1] of dlPFC and Implications for Transcranial Magnetic Stimulation (TMS) Targeting. *Diagnostics (Basel)*. 2023 Aug 16;13(16):2690. doi: 10.3390/diagnostics13162690. PMID: 37627949

178. Mahdavi KD, Jordan SE, Jordan KG, Rindner ES, Haroon JM, Habelhah B, Becerra SA, Surya JR, Venkatraman V, Zielinski MA, Spivak NM, **Bystritsky A**, Kuhn TP. A pilot study of low-intensity focused ultrasound for treatment-resistant generalized anxiety disorder. *J Psychiatr Res*. 2023;168:125-132. doi:10.1016/j.jpsychires.2023.10.039. PMID:39491902.
179. Hazan S, von Guttenberg M, Vidal AC, Spivak NM, **Bystritsky A**. A Convenience Sample Looking at Microbiome Differences Between Anxious and Non-Anxious Patients in a GI Clinic. *Gastroenterology Insights*. 2024;15(4):1054-1063. doi:10.3390/gastroent15040072.
180. Metts AV, Roy-Byrne P, Stein MB, Sherbourne CD, **Bystritsky A**, et al. Reciprocal and indirect effects among intervention, perceived social support, and anxiety sensitivity within a randomized controlled trial for anxiety disorders. *Behav Ther*. 2024;55(1):80-92. doi:10.1016/j.beth.2023.08.004. PMID:37949392.
181. Deveney CM, Surya JR, Haroon JM, Mahdavi KD, Hoffman KR, ... **Bystritsky A**, et al. Transcranial focused ultrasound for the treatment of tremor: a preliminary case series. *Brain Stimul*. 2024;17(1):35-38. doi:10.1016/j.brs.2023.09.005. PMID:37872371.
182. Papakostas GI, Trivedi MH, Shelton RC, Iosifescu DV, Thase ME, Jha MK, ... **Bystritsky A**, et al. Comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment resistant depression (ASCERTAIN-TRD): a randomized clinical trial. *Mol Psychiatry*. 2024;29(8):2287-2295. doi:10.1038/s41380-024-02468-x. PMID:38454079.
183. Guidetti C, Chaikali S, Trivedi MH, Shelton RC, Iosifescu DV, Thase ME, Jha MK, Mathew SH, DeBattista C, Dokucu ME, Brawman-Mintzer O, Hernández Ortiz JM, Currier GW, McCall WV, Modirrousta M, Macaluso M, **Bystritsky A**, Vila-Rodriguez F, et al. Comparative Effectiveness Research Trial... quality of life results (ASCERTAIN-TRD). *J Clin Psychiatry*. 2025;86(3):24m15614. doi:10.4088/JCP.24m15614. PMID:40801757.
184. Bishay AAED, Guo A, Desai R, Mushinski S, Au A, Swenson AJ, Iacoboni M, **Bystritsky A**, Spivak NM. Limited Potential of Repetitive Transcranial Magnetic Stimulation for Treatment of Essential Tremor: A Systematic Review. *NeuroSci*. 2024;5(4):523-533. doi:10.3390/neurosci5040038.
185. Bishay AAED, Swenson AJ, Spivak NM, Schafer ME, Monti MM, **Bystritsky A**, et al. Preliminary Examination of the Effects of Focused Ultrasound on Living Skin and Temperature at the Skin–Transducer Interface. *Bioengineering (Basel)*. 2024;11(11):1126. doi:10.3390/bioengineering11111126.
186. Hazan S, von Guttenberg M, Vidal AC, Spivak NM, **Bystritsky A**. A convenience sample looking at microbiome differences between anxious and non-anxious patients in a GI clinic. *Gastroenterology Insights*. 2024;15(4):1054-1063. doi:10.3390/gastroent15040072. PMID:39685921.

- 187.** Guidetti C, Chaikali S, Trivedi MH, Shelton RC, Iosifescu DV, Thase ME, ... **Bystritsky A**, et al. Effect of augmentation with aripiprazole or augmentation with repetitive transcranial magnetic stimulation versus switching to the antidepressant venlafaxine extended release in treatment-resistant depression: the ASCERTAIN-TRD trial. *J Affect Disord.* 2025;390:119836. doi:10.1016/j.jad.2025.119836. PMID:40079989.
- 188.** Guidetti C, Chaikali S, Trivedi MH, Shelton RC, Iosifescu DV, Thase ME, ... **Bystritsky A**, et al. Comparative Effectiveness Research Trial for Antidepressant Incomplete and Nonresponders With Treatment Resistant Depression (ASCERTAIN-TRD): Effect of Aripiprazole or rTMS Augmentation Versus Switch. *J Clin Psychiatry.* 2025;86(3):24m15614. doi:10.4088/JCP.24m15614. PMID:40801757.

RESEARCH PAPERS (non-peer reviewed)

1. **Bystritsky A.** Imipramine in panic/agoraphobia: Finding the dose, Clinical Psychiatry News, 22:5:2 & 21, 1994.
2. **Bystritsky A.** Pharmacological treatment of social phobia, Newsletter, Southern California Psychiatric Association, 1996.
3. Feusner J, **Bystritsky A.** Management of Treatment Resistant OCD, Psychiatric Times, XXII (8):18-22, 2005.

BOOKS/BOOK CHAPTERS

1. **Bystritsky A**, Martynichkin AV. The study of the tranquilizing action of lorazepam and chlordiazepoxide on the models of concurrent interaction, In: Valdman AV (Ed.). Psychopharmacology of Emotional Stress and Zoosocial Interactions, Medical Literature, Leningrad, 1975.
2. Katkova EB, **Bystritsky AS**, Martynichkin AV. The comparative effect of sidnocarbe and amphetamine on the emotional behavior act, In: Valdman AV (Ed.). Psychopharmacology of Emotional Stress and Zoosocial Interactions, Medical Literature, Leningrad, 1975.
3. Goldstein M, Lew JY, **Bystritsky A**, Liberman A, Engel J, Liljequist S. Multiple dopamine receptors: Interaction with alpha-2 receptors, In: Agnoli A, Crepaldi G, Spano PF, Trabucchi M (Eds.). Aging Brain and Ergot Alkaloids, 241-248. Raven Press, New York, 1983.
4. Pasnau RO, **Bystritsky A.** The anxiety disorders: A review, In: Kales A, Pierce C, Greenblatt M (Eds.). The Mosaic of Contemporary Psychiatry in Perspective, 1992.
5. Pasnau RO, **Bystritsky A.** Anxiety and depression, coexistence and comorbidity, In: Den Boer I (Ed.). Handbook of Anxiety and Depression, Elsevier, 1995.
6. **Bystritsky A**, Williams K., Treatment of Panic Disorder, In: Rakel and Bope (Eds.), Conn's Current Therapy Guide, Elsevier, 2005, 2006, 2007 editions.
7. **Bystritsky A.** Neuropharmacological and Therapeutic Aspects of Panic Disorders, St. Petersburg, 2006.
8. Rapgay L, **Bystritsky A.** Longevity & Optimal Health: Integrating Eastern and Western Perspectives. February 2008, edited by W. C. Bushell, MIT; & Eium L Olivo, Columbia University.
9. **Bystritsky A.** ABC of Anxiety, Self-Help Brochure, 2010
10. **Bystritsky A.** UP-TO-DATE section on GAD, Social Anxiety, Pharmacological Treatment of Anxiety and Alternative and Herbal Treatments of Anxiety.

LETTERS TO THE EDITOR

1. **Bystritsky A.** A case report of high dose klonopin dependence, Clinical Psychiatry, 1993.
2. **Bystritsky A**, Vapnik T. Dysmorphophobia group treatment, Letter, Peer Reviewed, Depress Anxiety, 5:39-40, 1997.

ABSTRACTS

1. Petriaevskaya NV, Nesterovich NA, Martynichkin AV, **Bystritsky A.** The Pharmacological regulation of acute and chronic stress in an experiment, In: Theses of the 4th All-Union Congress of Pharmacology, Leningrad, 1976.
2. **Bystritsky A**, Ware JE, Linn LS. Development of a four-dimensional anxiety scale, Abstracts of National Meeting of R.W.J. Clinical Scholars, Tampa, FL, 1988.
3. Shekim WO, **Bystritsky A**, Hess EB. Anxiety disorders and ADHD, New Research Abstracts, American Psychiatric Association, NR328, 1989.

Over 300 other abstracts, invited or honorary lectures or abstracts

MANUALS/SCALES

1. **Bystritsky A**, Ware JE, Linn LS. Four-Dimensional Anxiety Scale (FDAS) Manual, University of California, Los Angeles, 1988.
2. **Bystritsky A**, Selivra E, Bystirsky M. M.I.N.I Diagnostic Interview, Russian Translation, 1998, 2004.
3. Craske MG, Roy-Byrne PP, Stein MB, **Bystritsky A.** Collaborative Care Manual For Treatment of Panic In Primary Care, 2000, 2004.
4. **Bystritsky A.**, ABC of Anxiety, Treatment Manual and Brochure, Jan 2010

Patents:

Patent “Method of Modifying Electrical Currents in Neuronal Circuits”, USPTO 7,283,861 - 2002

18 more patents assigned to Brainsonix Corp. More patents are either pending or issued for Brainsonix Corporation

Clinical Trial Experience:

Phase I – IV

Anxiety Disorder

2014 Interventional, randomized, double blind, parallel group, placebo controlled, flexible dose study of brexpiprazole as adjunctive treatment to paroxetine or sertraline in adult patients suffering from post traumatic stress disorder (PTSD), Lundbeck, Phase III

2017 A randomized, double blind, placebo-controlled trial of adjunctive BHV 4157 in Obsessive Compulsive Disorder. Biohaven, Phase II

2018 A Prospective, Double Blind, Randomized, Controlled Study to Evaluate the Safety and Efficacy of the Brainsway (HAC Coil) deep Transcranial Magnetic Stimulation (DTMS) System for the Treatment of Post-Traumatic Stress Disorder (PTSD). Brainsway. Phase N/A.

2019 A Multicenter, Randomized, Double Blind, Placebo Controlled Trial of Troriluzole in Generalized Anxiety Disorder. Biohaven, Phase III.

2019 A Multicenter, Randomized, Double Blind of Fixed Dose Brexpiprazole as Combination Therapy with Sertraline in the Treatment of Adults With Post traumatic Stress Disorder, Phase III.

2021 A Phase II, 8-week-treatment, multicenter, randomized, doubleblind, placebo-controlled, parallel group trial to evaluate the efficacy, tolerability and safety of orally administered BI 1358894 in patients with Post-Traumatic Stress Disorder (PTSD), Phase II

2021 A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial of PH94B Nasal Spray for the Acute Treatment of Anxiety Induced by a Public Speaking Challenge in Adult Subjects with Social Anxiety Disorder, Phase III

2021 A Phase 3 Open-label Safety Trial of PH94B Nasal Spray in the Acute Treatment of Anxiety in Adult Subjects with Social Anxiety Disorder (SAD), Phase III

2021 A Phase 1b/2a Randomized, Double-Blind, Placebo Controlled, Parallel Study to Evaluate the Safety, Tolerability, and Efficacy of Two Doses of RLS103 (CBD Technosphere® Inhalation Powder) in Subjects with Performance Anxiety within Social Anxiety Disorder (SAD), Phase I

Depression

2013 Double Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX

Curriculum Vitae

Alexander Bystritsky, M.D., Ph.D.

13 in Subjects with Inadequate/Partial Response to Antidepressants during the Current Episode of Major Depressive Disorder, Naurex, Phase II

2013 A Double Blind, Placebo Controlled, Randomized Add On Study of MSI 195 (S Adenosyl L Methionine, SAME) For Patients With Major Depressive Disorder (MDD) Who Have Had An Inadequate Response to Current Antidepressant Therapy, Methylation Sciences Inc, Phase II

2014 A Double Blind, Placebo Controlled, Randomized Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder, Alkermes, Phase III

2014 A Multicenter Study of the Long-term Safety and Tolerability of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder in Adults who Have an Inadequate Response to Antidepressant Therapy, Alkermes, Phase III

2015 A Randomized, Double Blind, Placebo Controlled, Relapse Prevention Study Evaluating the Efficacy and Safety of Vortioxetine (5, 10 and 20 mg) in Adults With Major Depressive Disorder, Lundbeck Takeda, Phase IV

2015 An 8 Week Prospective Randomized, Controlled, Double Blind Trial of the Genecept Assay [™] vs. Treatment as Usual to Evaluate Efficacy of Assay Guided Treatment in Adults with Major Depressive Disorder, Genomind Inc., Phase III

2017 A 6 Month, Multicenter, Double Blind, Randomized, Flexible Dose, Parallel Group Study to Compare the Efficacy, Safety, and Tolerability of JNJ 42847922 versus Quetiapine Extended Release as Adjunctive Therapy to Antidepressants in Adult Subjects With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy. Janssen, Phase II

2018 Double Blind, Placebo Controlled, Phase 2 Trial to Test Efficacy and Safety of AV 101 (L 4 chlorokynurenine) as Adjunct to Current Antidepressant Therapy in Patients with Major Depressive Disorder (MDD) with an Inadequate Response to Current Antidepressants. Vistagen, Phase II

2018 – Augmentation versus Switch: Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non responders with Treatment Resistant Depression (ASCERTAIN TRD). Patient Centered Outcomes Research Institute (PCORI). Phase IV.

2018 – A Multicenter, Randomized, Double blind, Placebo controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole as Adjunctive Therapy in the Maintenance Treatment of Adults with Major Depressive Disorder. Otsuka. Phase III

2018 A Prospective Multicenter Double Blind Randomized Controlled Trial to Compare the Efficacy of the H7 Coil to H1 Coil Deep Transcranial Magnetic Stimulation (DTMS) in Subjects with Major Depression Disorder (MDD). Brainsway. Phase N/A.

2020 A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and

Tolerability of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants with Treatment-resistant Depression, Phase IV

2021 Evaluation of the Efficacy and Safety of Oral GATE-251 or Placebo for the Reduction of Symptoms of Major Depressive Disorder, Phase II

2022 A Double-Blind, Randomized, Parallel-Group Study with Quetiapine Extended Release as Comparator to Evaluate the Efficacy and Safety of Seltorexant 20 mg as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Disorder with Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy, Phase III

Schizophrenia

2013 A Multicenter 40 Week Extension Study to Evaluate the Safety and Clinical Effects of Prolonged Exposure to 1 and 2 mg Doses of EVP 6124, an Alpha 7 Nicotinic Acetylcholine Receptor Agonist, as an Adjunctive Pro cognitive Treatment in Subjects with Schizophrenia on Chronic Stable Atypical Antipsychotic Therapy, Envivo, Phase III

2015 A Randomized, Double Blinded, Placebo Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Four Orally Administrated Doses of BI 409306 during a 12 week Treatment Period in Patients with Schizophrenia on Stable Antipsychotic Treatment, Boehringer Ingelheim, Phase II

2020 A Phase IIIb Multi-Center, Open-Label, Mirror-Image, Trial in Adult Subjects with Schizophrenia Treated Prospectively for 6-months with Abilify MyCite, Phase III

Alzheimer's Disease

2015 A Placebo controlled, Double blind, Parallel group, Bayesian Adaptive Randomization Design and Dose Regimen finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease, Eisai, Inc., Phase II

2016 A Phase 3, double blind, randomized study of RVT 101 versus placebo when added to existing stable donepezil treatment in subjects with mild to moderate Alzheimer's disease. Axovant, Phase III

2021 A Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) for the treatment of agitation in patients with dementia of the Alzheimer's type

Obsessive Compulsive Disorder

2021 A Randomized, Double-Blind, Placebo-Controlled Trial of Adjunctive Troriluzole, Phase III

2021 A Multicenter, 48-week Open-Label Safety Study of Adjunctive Troriluzole in Subjects with Obsessive Compulsive Disorder, Phase III

Other Indications

2014 A Prospective, Double Blind, Randomized, Controlled Study to Evaluate the Safety and Efficacy of the Deep Transcranial Magnetic Stimulation (DTMS) (with the H ADD Coil) intended as an aid to Smoking Cessation, Brainsway

2015 A Randomized, Double blind, Placebo Controlled, Parallel group Trial with an Open label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women with Hypoactive Sexual Desire Disorder (HSDD) (with or without Decreased Arousal), Palatin Technologies Inc, Phase III

2015 A Randomized, Double Blind, Placebo and Active Controlled Study of DS 5565 in Subjects with Pain Associated with Fibromyalgia, Daiichi Sankyo, Phase III

2015 An Open Label Extension Study of DS 5565 for 52 Weeks in Pain Associated with Fibromyalgia, Daiichi Sankyo, Phase III

2016 A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine. Allergan, Phase III

2016 A Multicenter, Randomized, Open Label Extension Study to Evaluate the Long Term Safety and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine with or without Aura. Allergan, Phase III

2017 Prasterone (DHEA) For the Treatment of Hypoactive Sexual Desire Disorder (HSDD) (Placebo Controlled, Double Blind and Randomized Phase III Study of 24 Week Intravaginal Prasterone) Endoceutics, Phase III

2020 A Multicenter, Randomized, Flexible-dose, Double-blind Trial of Brexpiprazole Versus Placebo for the Treatment of Adults With Borderline Personality Disorder, Phase II

2020 A Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Adult Subjects With Borderline Personality Disorder, Phase III